#62 - Tobias Erny: Ibogaine for Parkinson's?

#62 - Tobias Erny: Ibogaine for Parkinson's?

What drives someone to seek a life-changing option when standard treatment hits a wall? This episode follows that question through the story of ibogaine and Parkinson’s, guided by researcher and practitioner Tobias Erny and host Talia Eisenberg. Aimed at people living with Parkinson’s, their families, and those curious about psychedelic medicine beyond addiction, the conversation stays grounded, careful, and very human.

Tobias describes how he met "Patient D" at an ibogaine conference in 2016 and watched a man who "couldn’t button a shirt" or feed himself go on to smile, dress, and eat independently after carefully managed low-dose ibogaine. He later helped publish a case report showing "an improvement of 50% or even better" across several Parkinson’s scales over 80 days, including a drop from eight hours of daily gait freezing to about half an hour.

You’ll hear accessible explanations of what Parkinson’s actually is, why dopamine neurons matter, and why environmental toxins like herbicides and pesticides might increase risk. Tobias breaks down possible mechanisms behind ibogaine’s effects, from boosting nerve growth factors to its antidepressant qualities that helped one man swap lonely days on the sofa for Tai Chi in the park. The tone stays refreshingly honest about limits.

Tobias stresses that ibogaine is "not a cure" but a "disease-modifying therapy" that may buy time and quality of life for some, and not work at all for others—around 40% in his experience. They dig into low-dose protocols, screening, cardiac risk, medication conflicts, and why unsupervised self-experimentation can be dangerous. Beyond the science, there’s a gentle focus on mindset: ibogaine sometimes shifts people from being "at war" with their illness to a more accepting, engaged stance toward life.

If you’re weighing psychedelic options alongside Parkinson’s, this conversation might help you form better questions for your next step.